Secondary Central Nervous System Lymphoma

Secondary Central Nervous System Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

16 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 9
Recruiting: 7
Ph III recruiting: 0
Growth YoY: —
Industry share: 22%
Top sponsor: Memorial Sloan Kettering Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–16 of 16 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03964090	Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)	active not recruiting	Phase 2	48	National Cancer Institute (NCI)NIH	1	Sep 4, 2026	clinicaltrials
NCT05351593	Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma	recruiting	Phase 1 / Phase 2	35	James RubensteinOTHER	1	Jul 14, 2026	clinicaltrials